Skin Substitute Rebate Programs: How DOJ Builds a Case and Where It Breaks Down
If you bought or sold amniotic allografts under a rebate agreement, the Justice Department now treats that agreement as the center of a criminal case. An indictment returned in the District of Nevada on August 4, 2026 charges a physician with concealing a 45 percent rebate, then rerouting the same money through a shell company after Medicare's contractor told providers to report rebates. The Department's National Fraud Enforcement Division is charging that structure in districts across the country.
Rebate programs were not a secret in wound care. Distributors marketed them openly. Sales representatives explained them on the first call. Billing companies built spreadsheets around them. For several years, they were simply how the skin substitute business worked.
Federal prosecutors now describe those same arrangements as kickbacks and the claims that followed them as false. That shift, not any change in the underlying conduct, is what has put physicians, nurse practitioners, clinic owners, distributors, and sales representatives under grand jury investigation.
This article explains how the government builds a rebate case, what it points to as evidence that a defendant knew better, and what it still has to prove. For a case-by-case breakdown of the four wound care indictments returned during the 2026 national enforcement action, see our analysis of the 2026 takedown wound care indictments.
How the Government Decides Who to Charge
A rebate scheme can involve dozens of people. Distributor executives, sales representatives, clinic owners, treating clinicians, billers, and the relatives whose names appear on marketing entities. The government charges a fraction of them.
Selection is driven by one question. Which individuals can the prosecution prove knew what they were doing, beyond a reasonable doubt, using documents a jury will understand without a tutorial. Suspicion about a person's role is not enough to indict. A wire transfer, a signed certification, and a text message quantifying the split usually are.
Two categories of people sit at the top of the list in every one of these cases.
The People Who Made the Most Money
Financial benefit is the government's proxy for intent and the organizing principle of its charging decisions. Prosecutors trace the money first, then work outward to the conduct that produced it. The person whose accounts received the largest share of the rebate stream is presumptively the person who understood the arrangement, and the presumption is difficult to dislodge once bank records are in evidence.
Profit also drives everything downstream of the charging decision. Forfeiture allegations reach gross proceeds. Guidelines calculations turn on loss and on the defendant's role. Purchases made with the money become the narrative the jury hears. Recent indictments in this space catalog yachts, exotic vehicles, jewelry, and real estate. None of that is an element of any offense. All of it is exhibit material.
Licensed Medical Professionals
Physicians, nurse practitioners, and other licensed clinicians are a standing enforcement priority. The Justice Department reports the number of licensed professionals charged in every takedown announcement, which reflects a deliberate policy choice rather than a coincidence of where the money went.
The reason is evidentiary as well as political. A clinician signs the Medicare enrollment certification agreeing to comply with program rules and the Anti-Kickback Statute. A clinician orders the product and signs the note supporting the claim. That paper trail gives prosecutors a knowledge theory they do not have against a warehouse employee or a back-office biller.
People outside those categories are often approached as cooperators rather than defendants. That is not generosity. A sales representative who accepts a plea and testifies about what the clinician was told converts a difficult intent case into a straightforward one. The government decides which role it wants a person to play well before it says so.
Why the Government Says a Rebate Is a Crime
Medicare pays for most Part B biologicals based on Average Sales Price, which manufacturers report quarterly. A new product has no ASP. Until one is published, the Medicare Administrative Contractor pays based on what the manufacturer or labeler charges the provider. CMS explains that methodology in its ASP pricing files.
That rule ties reimbursement directly to the invoice. Some allograft products carried list prices above $2,000 per square centimeter. One application to one wound could produce a claim in the tens of thousands of dollars.
A rebate breaks the assumption the rule depends on. The invoice says one number. After the rebate lands, the provider paid a much smaller number. Medicare paid on the larger one.
The government's theory follows from there. The claim represented a price the provider never actually paid. The rebate was money received in exchange for buying a product billed to Medicare. Those two propositions support charges under 18 U.S.C. § 1347 and the Anti-Kickback Statute at 42 U.S.C. § 1320a-7b.
Both statutes carry elements the government frequently struggles to satisfy in a pricing case. Our guides to defending health care fraud charges under 18 U.S.C. § 1347 and to Anti-Kickback Statute charges set out those elements, the available exceptions and safe harbors, and the defenses that apply to each.
The Rules Changed in the Middle of the Business
The dates drive the charges, and they arrived in the middle of the business.
In June 2022, the contractor administering Part B claims across several western states began requiring providers to report the total invoice price for allografts without a published ASP. It defined that term as the net amount paid after all discounts, rebates, refunds, or other adjustments.
In November 2022, the same contractor added a second requirement. A provider who billed the gross price, got paid, and then received a rebate had received an overpayment. The rebate had to be reported and refunded. The guidance stated that neither the timing of the rebate nor the name of the program changed that obligation.
Three federal authorities sit behind those instructions. The Medicare Claims Processing Manual directs contractors to price products without a published ASP using wholesale acquisition cost or invoice pricing. The Provider Reimbursement Manual states that the true cost of goods is the net amount actually paid, and that a discount, allowance, refund, or rebate must be used to reduce total cost. And providers must report and return identified overpayments within 60 days under the rule implemented at 42 C.F.R. § 401.305. Layered on top is the Anti-Kickback Statute's discount safe harbor at 42 C.F.R. § 1001.952(h), which protects a price reduction only when the rebate terms are fixed and disclosed in writing at the time of sale and the buyer accurately reports the reduction to the program.
A disclosed rebate that gets passed through to Medicare is lawful commerce. The same rebate becomes the government's fraud case when it is papered as something else and kept off the claim.
The Five Structures Charged So Far
Across criminal indictments and civil complaints filed since 2025, five arrangements recur. They differ in paperwork rather than economics. Each moves a share of the Medicare payment from the distributor back to the provider while the claim reports a price nobody paid.
1. The Undisclosed Percentage Rebate
The simplest version. A provider agrees to a fixed percentage back on every purchase, the invoice states gross list price, and the claim reports that gross figure. An indictment returned in the District of Nevada in August 2026 alleges a 45 percent rebate on allografts bought from two suppliers, papered as legitimate "Rebate Agreements" while concealing that the payments were consideration for placing orders. Claims went out at full invoice price. The physician kept the spread. That case alleges more than $95 million billed and more than $54 million paid.
2. The Dual Invoice
The distributor issues two invoices for the same product on the same day. One shows list price. One shows the price actually paid. The list price invoice exists solely to satisfy the contractor when it asks for documentation.
A civil complaint filed in the Southern District of Iowa in June 2026 describes the practice in detail. According to the United States, a plastic surgery practice received paired invoices from its distributor, responded to roughly 45 additional documentation requests with the inflated version only, and never disclosed the real price. On one product the reported price was $400 per square centimeter against $240 actually paid. On another, $800 against $480. The complaint alleges Medicare and TRICARE paid approximately $2.48 million on the resulting claims.
3. The Shell Company Pass-Through
A response to the reporting requirements rather than an alternative to them. The provider bills gross, receives payment, then remits the full Medicare payment to the supplier. The supplier routes it into an account it controls but holds in another entity's name, and a percentage returns from there.
The Nevada indictment alleges exactly that redesign in March 2023, with roughly 40 percent coming back through the pass-through account. The economics were nearly identical to the rebate it replaced. The paperwork was not. A payment that had looked like a rebate on a purchase now looked like a transfer from an unrelated company.
4. The Reimbursement Split
Common on the distributor side. Product ships at no upfront cost. The provider owes nothing if the claim is denied. Once the program pays, the distributor invoices a percentage of the reimbursement and the provider keeps the remainder. A 2026 indictment out of the Northern District of Texas alleges invoices set at 60 to 70 percent of reimbursement, leaving providers a guaranteed 30 to 40 percent margin on every paid claim, and roughly $94 million in payments to providers.
5. Commissions to Referral Sources
Percentage payments to people who send patients rather than to people who buy product. A Middle District of Florida indictment alleges sales representative agreements that functioned as per-referral compensation at 20 percent of invoiced product, with single-day payments of $397,570 and $10,998 to two representatives.
In each structure, the number on the claim and the number in the bank records diverge. Someone decided which one to report, and the government's case is an argument about who that was and what they understood.
What Prosecutors Offer as Proof of Intent
Rebates are ordinary in medical supply, and the government knows a jury will hear that. Charging documents therefore work to separate normal pricing from concealment. Five categories of proof do that work, and they recur across districts.
The Invoice Does Not Match the Money
The invoice supporting the claim states a price the parties never treated as final. Bank records show what actually moved. One 2026 indictment quotes an email asking a distributor for "invoices needed by Medicare" showing inflated prices. Another quotes a provider instructing her billing company, "invoice price 1600 charge 3900."
Money Moves Through Entities That Do Nothing
Pass-through accounts. Marketing companies with no employees. Entities nominally owned by a relative. One indictment alleges nearly $16 million routed to a family member's company. When the government cannot identify a service the entity performed, it argues the entity existed to hide the payment.
The Structure Changed After the Rules Did
This is the most damaging category and the newest. Where a payment path changes shortly after a contractor issues a reporting requirement, prosecutors treat the change itself as proof the defendant understood the original arrangement was not permitted. The Nevada indictment is built on that sequence.
Texts and Emails That State the Arithmetic
Percentages written out. Screenshots of calculator results. Commission spreadsheets tracking amounts ordered, invoiced, paid, and owed back per provider account. In one case, a defendant allegedly told a colleague she was not supposed to discuss money with him at all.
What Happened After the Audit Started
Charts amended after a contractor requested records. Conservative treatment notes added to files more than a year old. The Nevada indictment charges falsification of records produced in a post-payment claim review. Conduct after the audit turns a coverage dispute into a consciousness-of-guilt argument, and it does more damage than the underlying billing.
Signal, WhatsApp, and Disappearing Messages
Every charge in a rebate case turns on state of mind. Health care fraud under 18 U.S.C. § 1347 requires knowing and willful execution of a scheme to defraud. The Anti-Kickback Statute requires that the defendant acted knowingly and willfully, which the government must prove meant knowing the conduct was unlawful. Neither element can be established by billing data. Both are usually established by messages.
That is why encrypted and self-deleting messaging now shapes these investigations. Rebate arrangements are frequently negotiated on Signal, WhatsApp, or Telegram rather than corporate email. Sales representatives move providers onto those platforms as a matter of routine. Disappearing message timers get set to seven days, or twenty-four hours, or off entirely.
Why Prosecutors Focus On It
The Justice Department has been explicit about its posture. Its Evaluation of Corporate Compliance Programs directs prosecutors to examine policies governing personal devices and messaging applications, including ephemeral applications, and states that prosecutors will not accept at face value a claim that such communications are unavailable. Individual investigations follow the same instinct.
Three things happen when an investigator learns that a defendant used a disappearing message platform.
First, the government works around the missing content. Agents seize devices and extract what survives. They obtain the other side of the conversation from a cooperating distributor or representative whose settings differed. They subpoena the platform for metadata showing who communicated with whom and when, which can corroborate a timeline even where content is gone. Screenshots forwarded to a third party, or messages backed up to a cloud account, are recovered constantly.
Second, and more damaging, the government argues from the choice itself. Prosecutors tell juries that people who believe a business arrangement is lawful discuss it on company email. Moving the same conversation to an encrypted app with a deletion timer, particularly at the moment a contractor issues new reporting requirements, is offered as circumstantial proof of consciousness of guilt. Paired with a structural change in how the money moved, it does real damage.
Third, deletion after an investigation becomes known creates independent criminal exposure. Destroying or concealing records with intent to obstruct a federal investigation is chargeable under 18 U.S.C. § 1519, which carries up to 20 years. That is double the maximum for the underlying health care fraud count. Obstruction counts are also easier to prove, because they involve a discrete act rather than a contested pricing rule.
What the Defense Has to Work With
The government's inference is not automatic. Encrypted messaging is now the default on hundreds of millions of phones, and default retention settings apply to birthday plans and business conversations alike. Health care companies adopt these platforms for legitimate reasons, including the transmission of protected health information. A defendant who used Signal for everything, before and after the conduct at issue, presents a very different picture than one who switched platforms the week the guidance changed.
Timing, selectivity, and pattern carry the argument in both directions. Whether the app was in use long before any regulatory event. Whether the deletion setting was chosen or inherited from the default. Whether other participants in the same conversations retained everything. Whether anything was deleted after a subpoena or an agent contact, which is the line that separates an argumentative inference from a chargeable offense.
That record is reconstructed from device images, carrier and platform metadata, cloud backups, and the retained messages of everyone else in the thread. The government builds its version from the same sources.
What the Government Still Has to Prove
These are aggressive charging decisions resting on an unusual legal foundation. Five pressure points recur across districts.
The Duty Comes From Sub-Regulatory Guidance
The obligation to report a net price after rebates does not appear in a statute or in a regulation adopted through notice and comment. It appears in Medicare Administrative Contractor bulletins, in the Medicare Claims Processing Manual, and in the Provider Reimbursement Manual. The government treats those manuals as settled law. They are agency guidance, they were written decades before anyone billed an amniotic allograft, and the contractor instructions applying them to skin substitutes shifted over time and varied by jurisdiction.
Building criminal liability on that foundation raises fair notice problems. It also complicates the willfulness element, which the Anti-Kickback Statute requires and the fraud statutes effectively require in a pricing case. Conduct predating a contractor's guidance sits on materially different ground than conduct after it, and which contractor covered the practice matters.
A Rebate Is Not Automatically Remuneration for Referrals
Congress wrote a statutory exception for discounts, and the safe harbor recognizes that volume pricing is ordinary commerce. The question is whether a payment reduced the price and was reported, or whether it induced purchasing and was hidden. That turns on facts about disclosure and structure. It does not follow from the label on the agreement.
Knowledge Is Proved Person by Person
Where money moved through distributors, billing vendors, and nominee entities, the government has to connect intent to each defendant individually. A provider who never saw the distributor's internal commission math occupies different ground than the person who designed the model. A sales representative who did real marketing work under a contract someone else drafted is not the same defendant as the executive who set the percentages. Willfulness under the Anti-Kickback Statute requires proof the person knew the conduct was unlawful.
Reliance on Others Is a Live Defense
Pricing fields on claim forms are often populated by outside billing companies. Rebate agreements are frequently drafted by distributor counsel and presented to providers as compliant. Where a defendant disclosed the arrangement to a biller, a consultant, or a lawyer and followed the advice given, the government's intent case weakens substantially.
The Billed Number Is Not the Loss
Press releases lead with amounts billed. Sentencing turns on loss, which starts with amounts paid and should account for products actually delivered and services actually rendered. The distance between a $95 million headline and a defensible loss calculation frequently determines the outcome more than any trial issue.
How These Investigations Reach People
The sequence is consistent enough to recognize.
| Stage | What It Looks Like |
|---|---|
| Data analytics | Claims data flags a provider or a product as an outlier on volume, per-beneficiary billing, or graft size relative to wound size. |
| Contractor review | Additional documentation requests, prepayment review, post-payment audit, or an extrapolated overpayment demand. |
| Payment action | Suspension of Medicare payments based on a credible allegation of fraud, or revocation of billing privileges. |
| Parallel civil work | A civil investigative demand, often signaling a sealed False Claims Act complaint filed by a former employee or competitor. |
| Criminal escalation | Grand jury subpoenas to banks, billing companies, and distributors. Agent interviews of staff at home. Seizure warrants on accounts. |
Many people first learn they are under investigation when an agent contacts a former employee, or when a distributor's counsel calls about a subpoena naming their practice. By that point the government has usually had the bank records for months.
Where These Cases Are Being Charged
Wound care enforcement started in the desert Southwest and has spread well past it. Location matters more here than in most federal cases, because the investigating team is frequently nowhere near the practice.
Districts With Charged Skin Substitute Matters
| District | Nature of the Matter |
|---|---|
| District of Arizona | The original criminal allograft prosecution. Company owners sentenced in 2025 to 15.5 and 14 years, with a $309 million civil resolution. Additional defendants charged in 2025 and 2026. |
| District of Nevada | Multiple criminal cases involving providers and distributor kickbacks, including the August 2026 rebate and shell company indictment. |
| Southern District of Texas | Multi-state clinic operator charged in 2026 with hospice-patient applications, inflated invoice pricing, and distributor kickbacks routed to a family-owned entity. |
| Northern District of Texas | Distributor executive charged in 2026 over a reimbursement-split model and kickbacks to providers and sales representatives. |
| Middle District of Florida | Nurse practitioner and two registered nurse "sales representatives" charged in 2026 with per-referral commissions and unnecessary applications. |
| Southern District of California | 2026 charges over allograft claims billed under a provider number while the provider was in federal custody. |
| Southern and Northern Districts of Iowa | Civil False Claims Act complaint filed jointly in June 2026 over dual invoices submitted in response to contractor documentation requests. A separate Iowa practice resolved skin substitute allegations for $800,000. |
| Eastern District of Oklahoma | Civil resolution over skin substitute applications lacking required conservative wound care documentation. |
| Central District of California | Criminal sentences in 2026 for a podiatrist and an unlicensed associate who applied skin substitutes, plus a separate multimillion-dollar civil resolution involving place-of-service and reuse allegations. |
| Eastern District of Washington | Civil resolution involving an injectable amniotic product billed to Medicare and TRICARE. |
Iowa Shows the Theory Traveling
The Iowa complaint is the invoice-pricing theory stripped of the aggravating facts that usually accompany it. No hospice patients. No shell companies. No luxury purchases. The allegation is that a practice received two invoices for each product, sent the inflated one to the contractor when asked, and kept the difference.
It was filed jointly by the U.S. Attorneys for both Iowa districts against a single-physician plastic surgery practice, and the alleged government payment was roughly $2.48 million. Numbers in that range do not require a strike force. They require a data run and one Assistant U.S. Attorney. That is what makes the theory portable to any district in the country.
Philadelphia and the New Strike Force Footprint
On April 30, 2026, the Justice Department launched the West Coast Health Care Fraud Strike Force, pairing the Health Care Fraud Section with the U.S. Attorney's Offices for the District of Arizona, the District of Nevada, and the Northern District of California. The Department cited data showing schemes migrating into those districts.
On August 4, 2026, it expanded the Northeast Strike Force into Philadelphia, embedding Fraud Division attorneys with the Eastern District of Pennsylvania. The Department described the district as a center of health care industry activity and a longstanding venue for qui tam litigation, and it paired the announcement with a corporate accountability message. Eastern Pennsylvania has not yet produced a charged allograft case. It has the resources now, the industry concentration, and a whistleblower pipeline. Those expansions followed earlier ones into the District of Massachusetts and the District of Minnesota, and the Department created the National Fraud Enforcement Division on April 7, 2026, with health care fraud as its priority docket.
Which Districts Are Likely Next
Two indicators point the same direction.
The first is CMS's WISeR model, which took effect January 15, 2026 and applies prior authorization or prepayment review to a defined service list that includes skin substitutes. The model runs in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. Prepayment review generates exactly the record a prosecutor needs: a contemporaneous request for pricing and medical necessity documentation, and a provider's written response. Arizona, Texas, Oklahoma, and Washington have already produced skin substitute matters. New Jersey and Ohio have not.
The second is the strike force map itself. Philadelphia, Boston, and Minneapolis received dedicated resources within the last year and have not yet charged allograft cases. The established teams in South Florida, Houston, Dallas, Los Angeles, Detroit, Chicago, Brooklyn, Newark, and the Gulf Coast remain active, and a national rapid response capability allows the Section to charge anywhere.
For a distributor, that means potential venue in every district where a customer billed. For a provider, it means the prosecutor may be two time zones away and may already have charged a supplier who is now cooperating.
Defending Rebate and Skin Substitute Cases
Scott Armstrong served as an Assistant Chief in the Fraud Section's Health Care Fraud Unit. He has tried sixteen complex federal cases, nine of them health care fraud jury trials built on the medical necessity and kickback theories now driving allograft prosecutions. Drew Bradylyons spent over 12 years as a federal prosecutor, roughly eight of them at the Fraud Section, where he supervised the South Florida Strike Force. He then led the Financial Crimes and Public Corruption Unit at the U.S. Attorney's Office for the Eastern District of Virginia. Their investigations and prosecutions have involved more than $2 billion in claims to Medicare.
The firm has represented the founder of a health care startup in a Justice Department investigation of Medicare claims for skin substitutes, and the chief executive officer of a health care startup in a Justice Department investigation involving approximately $50 million in Medicare claims for skin substitute services.
The record that decides these cases is narrower than the indictment suggests. The purchase agreements as written. The settlement statements behind each invoice. Who populated the pricing field on the claim, and what they were told. What the contractor guidance said on each date at issue, and when the practice actually saw it. Who inside the organization made the decision, and who carried it out.
Four issues decide most of them. Whether a duty built on sub-regulatory manuals and contractor bulletins gave fair notice. What the client actually knew, which is where cases against executives and clinicians most often fail. What the cooperating distributor or sales representative said before the plea agreement, and what that agreement is worth to the witness. And whether the case is tried. The firm's wound care fraud defense and health care fraud and Anti-Kickback Statute defense practices cover providers, clinic owners, distributors, and sales representatives in investigations nationwide.
An indictment contains allegations only. Every defendant is presumed innocent unless and until proven guilty beyond a reasonable doubt.
Frequently Asked Questions
What is a skin substitute or allograft rebate program?
A rebate program is an arrangement in which a skin substitute distributor or manufacturer returns part of the purchase price to the provider after the sale. The invoice states a high list price. The provider bills Medicare based on that price. A percentage comes back afterward.
The structure mattered because of how Medicare paid. For allograft products with no published Average Sales Price, contractors set reimbursement from the price the provider reported paying. Some products listed above $2,000 per square centimeter, so a single application could generate a claim in the tens of thousands of dollars. A rebate widened the gap between the reported price and the real one.
Rebate percentages in charged matters have ranged from roughly 20 percent to 45 percent. Some arrangements were calculated as a share of the Medicare reimbursement rather than a share of the purchase price. Others took the form of paired invoices, a reimbursement split, or payments routed through a separate marketing entity.
Rebates are lawful in ordinary commerce. Federal prosecutors charge them under 18 U.S.C. § 1347 and 42 U.S.C. § 1320a-7b when the net price was not disclosed on the claim, when the rebate was never reported and returned as an overpayment, or when the payment functioned as consideration for purchasing rather than as a reduction in price.
Are rebates from skin substitute distributors illegal under the Anti-Kickback Statute?
Not by themselves. Rebates and volume discounts are ordinary in medical supply, and Congress wrote a statutory exception for discounts into the Anti-Kickback Statute. HHS-OIG implemented that exception through the discount safe harbor at 42 C.F.R. § 1001.952(h).
The safe harbor generally requires that the discount be given at the time of sale, or that rebate terms be fixed and disclosed in writing at the time of the initial sale, and that the buyer accurately report the reduction to the federal program. Compliance is voluntary, and an arrangement outside the safe harbor is not automatically unlawful.
What draws charges is concealment. The arrangements in recent wound care indictments share the same features: percentages never disclosed to Medicare, payments routed through entities that performed no identifiable service, and invoices stating prices the parties never treated as final. Where the rebate was disclosed and the net price was reported on the claim, the government’s theory does not get off the ground.
Does Medicare require providers to report rebates on allograft claims?
Yes, under contractor guidance, the CMS manuals, and federal overpayment law. For allograft products without a published Average Sales Price, Medicare Administrative Contractors have required providers to submit the total invoice price, meaning the net amount paid after all discounts, rebates, refunds, and other adjustments. One contractor imposed that requirement in June 2022 for providers in its jurisdiction.
A second requirement followed in November 2022. Where a provider billed the gross price, got paid, and later received a rebate, the difference was treated as an overpayment that had to be reported and refunded. The guidance stated that neither the timing of the rebate nor the label on the program affected the obligation.
Two CMS manuals sit behind those instructions. The Medicare Claims Processing Manual directs contractors to price products without a published ASP using wholesale acquisition cost or invoice pricing. The Provider Reimbursement Manual states that the true cost of goods is the net amount actually paid, and that a discount, allowance, refund, or rebate must reduce total cost.
Federal law separately requires reporting and returning identified overpayments within 60 days. All of these now appear as building blocks in criminal charging documents, which is why the effective dates of the contractor guidance carry real weight in these cases.
How does the government prove a rebate was a disguised kickback?
Almost entirely through documents. Prosecutors compare the invoice supporting each claim against bank records showing what the provider actually paid and what came back. They obtain distributor commission spreadsheets tracking amounts ordered, invoiced, and owed per account. They trace funds through pass-through accounts and nominee entities.
Communications do the heaviest work at trial. Recent charging documents quote emails requesting invoices at inflated prices for submission to Medicare, instructions to billing companies specifying a charge well above cost, and messages warning colleagues not to discuss payment amounts.
A June 2026 civil complaint out of Iowa illustrates the documentary method. The United States alleged that a distributor sent a practice two invoices for each product on the same day, one at list price and one at the price actually paid, and that only the inflated version went to the contractor in response to roughly 45 documentation requests.
Timing evidence has become central. Where a payment structure changes shortly after a contractor issues a rebate reporting requirement, prosecutors argue the change itself shows the defendant knew the original arrangement was not permitted. The August 2026 District of Nevada indictment rests substantially on that inference.
Is reliance on a billing company or distributor a defense to health care fraud charges?
It can be, and it is one of the most important issues in these cases. Both the health care fraud statute and the Anti-Kickback Statute require proof of knowledge and intent, and the Anti-Kickback Statute requires willfulness, meaning the government must show the person knew the conduct was unlawful.
In practice, pricing fields on claim forms are frequently completed by outside billing vendors. Rebate agreements are commonly drafted by distributor counsel and presented to providers as compliant arrangements. Where a provider disclosed the terms to a biller, consultant, or attorney and followed the guidance received, that history undercuts the government’s intent case.
The strength of the defense depends on the record: what the provider was told, what was disclosed to whom, whether the disclosure was complete, and whether the reliance was reasonable. Formal advice-of-counsel reliance carries its own consequences, including waiver of privilege over the advice at issue.
Prosecutors anticipate this argument and try to defeat it with evidence that the defendant received compliance warnings and proceeded anyway. That is one reason internal communications matter so much in these investigations.
Can Signal, WhatsApp, or disappearing messages be used as evidence of criminal intent?
Yes, in two distinct ways. Where content survives on a device, in a cloud backup, or on the other participant’s phone, it comes in as direct evidence. Where content is gone, prosecutors argue from the choice of platform itself, telling juries that people who believe an arrangement is lawful do not move the conversation to an encrypted app with a deletion timer.
That argument carries weight because intent is the contested element in nearly every rebate case. Health care fraud requires knowing and willful conduct, and the Anti-Kickback Statute requires proof that the defendant knew the conduct was unlawful. Billing data cannot establish either. Messages routinely do.
Deletion after an investigation becomes known creates separate exposure. Destroying or concealing records with intent to obstruct a federal investigation is chargeable under 18 U.S.C. § 1519 and carries up to 20 years, double the maximum for the underlying health care fraud count. A federal grand jury subpoena itself warns that altering or destroying responsive documents may constitute obstruction.
The inference is contestable. Encrypted messaging is the default on most phones, and health care companies adopt these platforms for legitimate reasons including transmission of protected health information. What matters is pattern and timing: whether the platform was in use long before any regulatory event, whether the retention setting was chosen or inherited, and whether anything was deleted after a subpoena or agent contact.
Did the January 2026 CMS payment change end skin substitute fraud exposure?
No. The change is prospective, and it does not shorten the government’s reach backward.
Effective January 1, 2026, CMS reclassified most skin substitutes as incident-to supplies rather than biologicals and set a single national rate of approximately $127 per square centimeter, replacing ASP-based payment that exceeded $2,000 per square centimeter for some products. CMS made the change after Medicare Part B spending on these products grew from roughly $252 million in 2019 to more than $10 billion in 2024, and projected a reduction near 90 percent.
That removes the economic incentive going forward. It does nothing about 2021 through 2025. The claims data for those years exists, the five-year criminal limitations period reaches back into 2021, and the False Claims Act reaches six years and in some circumstances ten. Every wound care case charged in 2026 concerns conduct predating the rate change.
Scrutiny also increased in 2026 rather than easing. CMS’s WISeR model, effective January 15, 2026, applies prior authorization or prepayment review to skin substitutes in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. Those reviews generate contemporaneous written records of pricing and medical necessity representations, which is the same material prosecutors build cases on.
What is the statute of limitations for health care fraud and Anti-Kickback Statute charges?
Five years for the criminal charges most often brought in skin substitute cases. Under 18 U.S.C. § 3282, the general federal limitations period of five years applies to health care fraud under 18 U.S.C. § 1347, conspiracy under 18 U.S.C. § 1349, conspiracy to defraud the United States under 18 U.S.C. § 371, Anti-Kickback Statute violations, and money laundering under 18 U.S.C. § 1957.
Conspiracy charges reach further in practice. The period runs from the last act in furtherance of the agreement, so a conspiracy alleged to have continued into 2025 can bring conduct from 2020 or earlier before the jury as part of the scheme.
Civil exposure runs longer. The False Claims Act permits an action within six years of the violation, or within three years after the responsible government official knew or should have known the material facts, but never more than ten years after the violation.
Prosecutors approaching the end of a limitations period frequently ask individuals under investigation to sign tolling agreements that extend the deadline. Whether to sign is a strategic decision with real consequences in both directions, and it is generally the first meaningful negotiation in a wound care investigation.
Which federal districts are charging skin substitute and wound care cases?
The footprint now spans criminal and civil matters in Arizona, Nevada, the Southern and Northern Districts of Texas, the Middle District of Florida, the Southern and Central Districts of California, the Eastern District of Oklahoma, the Eastern District of Washington, and both districts of Iowa. Arizona produced the first criminal allograft prosecution. Nevada produced the August 2026 rebate and shell company indictment.
Iowa is the significant recent development. In June 2026, the U.S. Attorneys for both Iowa districts jointly filed a civil False Claims Act complaint alleging that a single-physician practice submitted inflated invoices in response to contractor documentation requests, with roughly $2.48 million in government payments. That case shows the invoice-pricing theory does not require a strike force or a nine-figure loss to bring.
Two indicators point to where cases arrive next. CMS’s WISeR model, effective January 15, 2026, applies prior authorization or prepayment review to skin substitutes in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. New Jersey and Ohio have not yet produced charged skin substitute matters. Separately, the Justice Department placed strike force resources in Philadelphia in August 2026 and in Massachusetts and Minnesota before that, and none of those districts has charged an allograft case yet.
Are distributors and sales representatives being charged, or only providers?
Both. Recent indictments reach the supply side directly. One 2026 case out of the Northern District of Texas charges the owner of a group of skin substitute companies over a reimbursement-split model in which product shipped at no upfront cost and the company invoiced providers for only 60 to 70 percent of the reimbursement received, leaving the provider a guaranteed margin on every paid claim. That indictment alleges roughly $94 million paid to providers and $27 million to sales representatives.
Sales representatives have been charged under the Anti-Kickback Statute where commissions are characterized as payment for referring patients rather than compensation for marketing. In a Middle District of Florida case, registered nurses who signed representative agreements were charged alongside the treating clinician, with single-day payments of $397,570 and $10,998 identified as kickbacks.
Exposure is individual. A representative who performed real marketing work under a contract drafted by others stands in a materially different position from the executive who designed the payment structure, and the government must prove willfulness as to each person separately. Representatives are also frequently approached as cooperating witnesses before any charging decision is made.
What are the early signs of a federal skin substitute investigation?
The sequence tends to follow a pattern. Claims data flags outlier billing. The Medicare contractor issues additional documentation requests, moves the provider to prepayment review, or completes a post-payment audit with an extrapolated overpayment demand. Payment suspension based on a credible allegation of fraud can follow, along with revocation of billing privileges.
In skin substitute matters, documentation requests seeking the invoice for a specific product on a specific date carry particular significance. Those requests are how contractors set the reimbursement amount, and the responses to them have become the central exhibits in recent pricing cases.
A civil investigative demand often signals a sealed False Claims Act complaint filed by a former employee, a competitor, or a distributor insider.
Criminal escalation is visible in different ways. Grand jury subpoenas to banks, billing companies, and distributors. Agents interviewing current or former staff at their homes, usually in the evening. Seizure warrants on operating accounts. Many people learn about an investigation indirectly, through a former employee or a supplier’s counsel, well after the government has obtained the financial records.
What does it mean to receive a target letter in a wound care fraud investigation?
A target letter is written notice that the prosecutor considers the recipient a putative defendant. Under Justice Manual 9-11.151, a target is a person as to whom the prosecutor or grand jury has substantial evidence linking that person to the commission of a crime and who, in the prosecutor’s judgment, is a putative defendant. A subject is a person whose conduct falls within the scope of the investigation. A witness is neither.
The distinction has practical weight. Target status means the evidence has largely been gathered and a charging decision is close. Subject status means the investigation is still developing and the designation can move in either direction. Status can also change over time, and the Justice Manual contemplates notification when target status ends.
Target letters ordinarily advise that the recipient may decline to answer questions, that anything said may be used later, and that documents responsive to a grand jury subpoena must not be altered or destroyed. That last warning is not boilerplate. Destruction of records after notice is separately chargeable.
In skin substitute matters, target letters frequently follow a documented rebate arrangement traced through bank records, or a cooperating distributor executive who has already resolved a case. Recipients are often the largest financial beneficiaries or the licensed clinicians whose certifications supply the government’s knowledge theory.
What are the penalties for skin substitute fraud under 18 U.S.C. § 1347?
Health care fraud under 18 U.S.C. § 1347 carries up to 10 years per count, and each claim can be charged as its own count. Conspiracy under § 1349 carries the same maximum as the completed offense. Anti-Kickback Statute violations carry up to 10 years per count. Transactional money laundering under § 1957 carries up to 10 years per transaction. Obstruction under § 1519 carries up to 20 years.
Sentencing turns primarily on loss under the federal guidelines. That is why the gap between amounts billed and amounts paid, and any credit for products actually delivered and services actually rendered, drives outcomes more than the count structure does. Recent allograft sentences have reached 14 and 15.5 years where loss figures ran into nine and ten figures.
Forfeiture allegations reach gross proceeds rather than profit, which permits pretrial seizure of bank accounts, real property, and vehicles before any trial date is set.
Collateral consequences frequently exceed the sentence. Conviction triggers mandatory exclusion from federal health care programs, restitution, and state licensing action. For clinicians, exclusion often ends the practice regardless of the term imposed.
Has Armstrong & Bradylyons handled skin substitute and allograft investigations?
Yes. The firm has represented the founder of a health care startup in a Justice Department investigation of claims submitted to Medicare for skin substitutes. The firm has also represented the chief executive officer of a health care startup in a Justice Department investigation involving approximately $50 million in Medicare claims for skin substitute services. Both matters turned on the issues at the center of the current enforcement wave: how product pricing was represented on claims, how the distributor arrangement was structured and documented, and what the individual executive actually knew.
Scott Armstrong served as an Assistant Chief in the Fraud Section’s Health Care Fraud Unit and tried sixteen complex federal cases, including nine health care fraud jury trials built on the medical necessity and kickback theories charged in current allograft cases. Drew Bradylyons served over 12 years as a federal prosecutor, including approximately eight years at the Fraud Section, where he supervised the Health Care Fraud Unit’s South Florida Strike Force and investigated matters involving more than $1 billion in alleged false claims. He later led the Financial Crimes and Public Corruption Unit at the U.S. Attorney’s Office for the Eastern District of Virginia. Their investigations and prosecutions have involved more than $2 billion in claims to Medicare.
With Special Counsel Andrea Savdie, a former Fraud Section trial attorney, the firm brings more than 25 years of combined Justice Department experience and 25 federal jury trials to its health care fraud and Anti-Kickback Statute defense practice, representing providers, clinic owners, distributors, and sales representatives nationwide.
How does the firm defend a skin substitute rebate case?
The approach starts with the rules the government is relying on. The duty to report a net price after rebates comes from Medicare contractor bulletins and the CMS manuals rather than from a statute or a notice-and-comment regulation, and that guidance shifted over time and varied by contractor. Establishing exactly what the applicable rule was on each date at issue, and whether it gave fair notice, narrows the case before any factual dispute is reached.
The second line of attack is intent. Both the health care fraud statute and the Anti-Kickback Statute require knowledge, and the Anti-Kickback Statute requires willfulness. Where the pricing field was populated by an outside biller, where the rebate agreement was drafted by distributor counsel and presented as compliant, or where the client never saw the distributor’s internal commission math, the government’s proof of a guilty state of mind is thin regardless of how the numbers look.
The third is the cooperating witness. These cases are frequently built on a distributor executive or sales representative who pleaded guilty and is testifying to reduce a sentence. Cross-examination on the terms of the agreement, the exposure avoided, the prior inconsistent statements, and the witness’s own conduct is often the decisive event at trial.
The last is trial. The firm’s partners have tried 25 federal jury cases between them, including health care fraud trials on the same medical necessity and kickback theories charged in current allograft prosecutions.
Under Investigation for Allograft Billing or a Rebate Arrangement?
Armstrong & Bradylyons PLLC defends physicians, nurse practitioners, clinic owners, distributors, and sales representatives in federal investigations involving skin substitute pricing, rebate agreements, and the Anti-Kickback Statute. Both founding partners previously served in the Justice Department component now bringing these cases.
